
    
      To evaluate the antidepressant effects of daily, active TMS (when compared with sham
      treatment) in adolescents meeting criteria for Major Depressive Disorder, single or recurrent
      episode (Phase I).

      Secondary:

      To evaluate the acute and long term safety of TMS treatment in adolescent MDD subjects.

      To evaluate the durability of benefit of TMS treatment over the course of 6 months in
      subjects who received clinical benefit from acute treatment course(s) (Phase III).

      To evaluate the benefit of daily, active, open-label TMS in Phase I subjects who did not
      receive protocol-defined clinical benefit; as new acute treatment (sham to active) or as
      extended treatment course (blinded active to open label active) (Phase II).
    
  